Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Werner

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
American Journal of Public Health|April 1, 1990
Prevalence of markers for hepatitis B and hepatitis D in a municipal house of correctionM A Barry, D Gleavy, K Herd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2001
Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipientsJ A DesJardin, E Cho, S Supran, et al.
Kidney International|July 1, 1977
Host responses to hepatitis B infection in patients in a chronic hemodialysis unitW T London, J S Drew, E D Lustbader, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 1, 1997
Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study GroupM E Falagas, D R Snydman, J Griffith, et al.
Lancet (London, England)|September 11, 1976
Host responses to hepatitis-B infection in patients with primary hepatic carcinoma and their families. A case/control study in Senegal, West AfricaB Larouze, G Saimot, E D Lustbader, et al.
The Journal of Infectious Diseases|January 1, 1988
Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumoniaD W Hecht, D R Snydman, C S Crumpacker, et al.
Transplantation Proceedings|February 1, 1993
Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study GroupB G Werner, D R Snydman, R Freeman, et al.
Clinical Transplantation|November 15, 1997
Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study GroupM E Falagas, D R Snydman, R Ruthazer, et al.
Transplantation|August 1, 1991
Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysisJ Tsevat, D R Snydman, S G Pauker, et al.
Hepatology (Baltimore, Md.)|March 1, 1985
Epidemiology and clinical impact of hepatitis D virus (delta) infectionI M Jacobson, J L Dienstag, B G Werner, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
American Journal of Public Health|April 1, 1990
Prevalence of markers for hepatitis B and hepatitis D in a municipal house of correctionM A Barry, D Gleavy, K Herd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2001
Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipientsJ A DesJardin, E Cho, S Supran, et al.
Kidney International|July 1, 1977
Host responses to hepatitis B infection in patients in a chronic hemodialysis unitW T London, J S Drew, E D Lustbader, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 1, 1997
Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study GroupM E Falagas, D R Snydman, J Griffith, et al.
Lancet (London, England)|September 11, 1976
Host responses to hepatitis-B infection in patients with primary hepatic carcinoma and their families. A case/control study in Senegal, West AfricaB Larouze, G Saimot, E D Lustbader, et al.
The Journal of Infectious Diseases|January 1, 1988
Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumoniaD W Hecht, D R Snydman, C S Crumpacker, et al.
Transplantation Proceedings|February 1, 1993
Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study GroupB G Werner, D R Snydman, R Freeman, et al.
Clinical Transplantation|November 15, 1997
Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study GroupM E Falagas, D R Snydman, R Ruthazer, et al.
Transplantation|August 1, 1991
Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysisJ Tsevat, D R Snydman, S G Pauker, et al.
Hepatology (Baltimore, Md.)|March 1, 1985
Epidemiology and clinical impact of hepatitis D virus (delta) infectionI M Jacobson, J L Dienstag, B G Werner, et al.
Pageof 6